Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ML29
- Development stage
- Preclinical
- Lead developer
- Medigen Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
ML29 is an investigational, live-attenuated reassortant arenavirus vaccine candidate being developed for the prevention of Lassa fever. It is a reassortant virus containing the L genomic segment (encoding the RNA-dependent RNA polymerase and Z protein) of the nonpathogenic Mopeia virus (MOPV) and the S genomic segment (encoding the nucleoprotein and glycoprotein precursor) of the pathogenic Lassa virus (LASV). ML29 was originally developed at the Institute of Human Virology at the University of Maryland School of Medicine and is licensed to Medigen. It has demonstrated safety, immunogenicity, and protective efficacy in various animal models, including guinea pigs and non-human primates, by inducing robust cell-mediated immunity.
- Other names
- Mopeia-Lassa reassortant clone ML29Mopeia-Lassa reassortant ML29 virusMopeia/Lassa reassortant 29reassortant ML29 virusrecombinant ML29
Beyond the preview
Go deeper on ML29.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ML29.